Mirvetuximab Soravtansine Fails to Delay Disease Progression in FRα-positive Ovarian Cancers, Trial Shows
News
Mirvetuximab soravtansine, an investigational antibody-drug conjugate targeting the folate receptor alpha (FRα) protein, was no better than chemotherapy at delaying disease progression or death in ovarian cancer patients included in ... Read more